ArticleThe Journal of investigative dermatology2015
Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use.
Article in The Journal of investigative dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Racial, Ethnic, and Sex Disparities in Nail Psoriasis Clinical Trials: A Systematic Review.Skin appendage disorders · 2022Pooled it
- The Importance of Sex Stratification in Autoimmune Disease Biomarker Research: A Systematic Review.Frontiers in immunology · 2018Pooled it
- Unmet needs in the management of psoriasis in Latin America: a systematic review.Anais brasileiros de dermatologiaPooled it
- Oral Chinese herbal medicine for psoriasis vulgaris: protocol for a randomised, double-blind, double-dummy, multicentre clinical trial.BMJ open · 2017Trial
- Assessment of Major Adverse Cardiovascular Event Across Diverse Racial Groups of Psoriasis Patients on Biologic Therapy: A Retrospective Cohort Study.The Journal of dermatology · 2026Article
- Global health and economic impact of expanding the WHO essential medicines list for psoriasis: a health economic modelling study.EClinicalMedicine · 2026Article
- Prescribing of high-cost targeted therapies in England is diverging by region.Public health in practice (Oxford, England) · 2026Article
- Efficacy and Safety of Tildrakizumab in Elderly Patients With Psoriasis: A Narrative Review.The Journal of clinical and aesthetic dermatology · 2026Review
- Establishment of the Kenyan Psoriasis Registry: A Case-Control Cohort.Dermatology and therapy · 2026Article
- Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification.Dermatology and therapy · 2025Article
- Factors Influencing Adherence to Phototherapy in Patients With Psoriasis: A Cross-Sectional Study.Journal of advanced nursing · 2025Article
- Psoriasis in People With Skin of Color: An Evidence-Based Update.International journal of dermatology · 2025Review
- Exploring racial, ethnic, and gender treatment differences in patients with psoriasis.Archives of dermatological research · 2025Article
- Inflammatory Skin Disease in Latin America: Treatment Challenges and Opportunities.Journal of inflammation research · 2025Review
- Racial disparities in length of hospitalization and systemic medication utilization in patients with psoriasis.Archives of dermatological research · 2024Article
- Redefining Disease Severity with Special Area Involvement and Reflecting on Treatment Patterns in a Real-World Psoriasis Population.Dermatology and therapy · 2024Article
- Patient perspective on psoriasis: Psychosocial burden of psoriasis and its management in Malaysia.PloS one · 2024Article
- Assessing the Quality, Comprehensiveness, and Readability of Online Patient Health Resources About Psoriasis in Skin of Color.The Journal of clinical and aesthetic dermatology · 2023Article
- Psychosocial Burden of Psoriasis: A Systematic Literature Review of Depression Among Patients with Psoriasis.Dermatology and therapy · 2023Review
- Comorbidity Burden and Treatment Patterns of Psoriasis in Vietnam: Real-World Data from the EXPAND Study.Dermatology and therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Psoriasis is a common chronic inflammatory disorder, primarily of the skin. Despite an aging population, knowledge of the epidemiology of psoriasis and its treatments among the elderly is limited. We examined the prevalence of psoriasis and its treatments, with a focus on biologics and identification of factors associated with biologic use, using a nationally representative sample of Medicare beneficiaries in 2011. On the basis of several psoriasis identification algorithms, the claims-based prevalence for psoriasis in the United States ranged from 0.51 to 1.23%. Treatments used for moderate-to-severe psoriasis (phototherapy, oral systemic, or biologic therapies) were received by 27.3% of the total psoriasis sample, of whom 37.2% used biologics. Patients without a Medicare Part D low-income subsidy (LIS) had 70% lower odds of having received biologics than those with LIS (odds ratio 0.30; 95% confidence interval, 0.19-0.46). Similarly, the odds of having received biologics were 69% lower among black patients compared with white patients (0.31; 0.16-0.60). This analysis identified potential financial and racial barriers to receipt of biologic therapies and underscores the need for additional studies to further define the epidemiology and treatment of psoriasis among the elderly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.